Karyopharm is committed to supporting Investigator Sponsored Trials (ISTs) globally as part of the development process of Karyopharm compounds. Support of ISTs may be provided in the form of drug supply only or drug supply with funding.
All requests will be vetted internally to ensure such request satisfies Karyopharm’s objective criteria and medical/scientific goals.
Researchers interested in Karyopharm’s IST program are required to first contact Karyopharm for a preliminary discussion of their research proposal.
After your preliminary discussion with Karyopharm, we welcome you to submit your request via our PORE® Request Management System.
Once on the PORE® website, please register and then log in to submit the required fields (be prepared with your current CV, ICH GCP Training Certification, and Budget, if applicable). Notifications regarding the status of the review will be communicated via email.
Karyopharm supports independent, unsolicited research relating to disease areas of interest to Karyopharm or relating to Karyopharm’s products through its Investigator Sponsored Trials (“IST”) program in order to advance research and enhance disease understanding. IST investigators and/or their affiliated institutions assume responsibility for all aspects of the study, including design, regulatory approval, initiation, and conduct and monitoring of the study, and analysis and publication of the results, in accordance with the Investigator Initiated Clinical Trial Agreement. IST proposals submitted to Karyopharm are reviewed for scientific merit as well as safety, legal, ethical, and budgetary considerations. Support for approved proposals may be provided in the form of drug supply only or drug supply with funding as requested in the study design. This program is open to physicians, researchers and institutions interested in conducting their own research.